Compositions and methods for treatment of cystic fibrosis
AssigneeVertex Pharmaceuticals Incorporated
InventorsCathy Chu, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Kirk A. Overhoff, Sarah Robertson, David Waltz
Life of this patent
Estimating the term…
Abstract
Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.
Claims20
A method of treating cystic fibrosis comprising administering to a patient in need thereof:
- (A) 400 mg to 1600 mg of at least one compound chosen from Compound I:
- and pharmaceutically acceptable salts thereof daily;
- and
- (B) 25 mg to 200 mg of at least one compound chosen from Compound II:
- and pharmaceutically acceptable salts thereof daily;
- and
- (C) 50 mg to 800 mg of at least one compound chosen from Compound III:
- and pharmaceutically acceptable salts thereof daily.
-33. (canceled)
-65. (canceled)
-127. (canceled)
A single tablet comprising a first solid dispersion, a second solid dispersion, and a third solid dispersion,
- (a) wherein the first solid dispersion comprises 50 mg to 800 mg of Compound I:
- and 10 wt % to 60 wt % of a polymer relative to the total weight of the first solid dispersion;
- (b) wherein the second solid dispersion comprises 3 mg to 70 mg of Compound II:
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion;
- and
- (c) wherein the third solid dispersion comprises 10 mg to 400 mg of Compound
- and 10 wt % to 30 wt % of a polymer relative to the total weight of the third solid dispersion.
-164. (canceled)
-196. (canceled)
A single tablet comprising a solid dispersion comprising 50 mg to 800 mg of Compound I:
- 3 mg to 70 mg of Compound II:
- 10 mg to 400 mg of Compound III:
- and
- one or more polymers.
-256. (canceled)
-265. (canceled)
A pharmaceutical composition comprising a solid dispersion comprising:
- (a) Compound I
- and (b) a polymer;
- and
- a pharmaceutically acceptable carrier.
-284. (canceled)
-318. (canceled)
Dependencies are inferred from the claim text.